Ocular Therapeutix Inc (NASDAQ:OCUL)
| 5.26 Delayed Data As of 4:00pm ET |  +0.095 / +1.84%Today’s Change | 2.57 Today|||52-Week Range 6.53 | +87.01% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $382.9M |
Company Description
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Contact Information
Ocular Therapeutix, Inc. 24 Crosby Drive Bedford Massachusetts 01730 |
Employees
Shareholders
| Other institutional | 37.73% |
| Individual stakeholders | 30.76% |
| Mutual fund holders | 14.22% |
Top Executives
| Antony Mattessich | President, Chief Executive Officer & Director |
| Donald Notman | Chief Financial Officer |
| Peter Jarrett | Chief Scientific Officer |
| Rabia Gurses Ozden | Chief Medical Officer |
| Karen-Leigh Edwards | Senior Vice President-Technical Operations |
